Zydus Wellness Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹14,716 Cr
- P/E
- 66.41
- ROE
- 3.98%
- PEG
- -6.34
- Price to sales
- 3.26
- Debt to equity
- 0.55
- 52W high / low
- ₹602 / ₹374
- Sales growth (5Y)
- 16.24%
- EBITDA margin
- 13.13%
- Net profit margin
- 5.78%
- Promoter holding
- 69.64%
- Sales (last year)
- ₹4,537 Cr
Zydus Wellness operates as an integrated consumer Company with business encompassing the entire value chain in the development, production, marketing and distribution of health and wellness products. The product portfolio of the Company includes brands like Sugar free, Everyuth and Nutralite.(Source : 202003 Annual Report Page No: 83)
Guidance scorecard · Q1 FY27 call
What Zydus Wellness Ltd's management guided
and where it ranks in Food Products
Food Products
RevenueQ1 FY27 call
10–20%- The company expects continued double-digit growth, maintaining strong momentum in both domestic and international markets.
- Protein portfolio growth is expected to diversify, with bars currently leading but beverages and snacks also showing substantial potential over the next three years.
- Innovations like new protein bars (millet-based wafer bars), traditional products (Roots), Korean chips, RTDs, and expanded Max Protein cookies aim to drive faster acceptance and growth.
- Comfort Click is EPS accretive and expected to increase margins and profit before tax, with ongoing international expansion including the U.S. and Middle East.
- Complan is growing well despite category degrowth, driven by segmented nutrition offerings and new formats like RTD beverages.
2 more points from Zydus Wellness Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY27 call
FlatSee what Zydus Wellness Ltd said on margins — free account, 30 seconds.
CapexQ1 FY27 call
Planned- There is a focus on expanding product portfolios (e.g., new protein bars, RTDs, Korean chips) and distribution reach, which may imply ongoing strategic investments in innovation and market expansion.
- The company is investing in brand building, particularly in Comfort Click, including digital-first consumer engagement and expanding presence in new markets like the U.S. and Middle East.
- They are strengthening infrastructure for quick commerce and expanding offline distribution selectively, which might involve capital investment.
2 more points from Zydus Wellness Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ1 FY27 call
See what Zydus Wellness Ltd said on fundraising — free account, 30 seconds.
Order bookQ1 FY27 call
Ask what Zydus Wellness Ltd said on the order book →
Full Q1 FY27 analysisRanges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Food Products
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Food Products companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹459 Cr | 7.9 | |
| 2 | 40%+ | Up 2%+ | ₹454 Cr | 79.8 | |
| 3 | 40%+ | Flat | ₹1,061 Cr | 48.2 | |
| 4 | 40%+ | Flat | ₹157 Cr | 10.5 | |
| 5 | 20–40% | Up 2%+ | ₹671 Cr | 48.3 | |
| 6 | 20–40% | Up 2%+ | ₹265 Cr | 7.8 |
Sign up free to see every company in the sector ranking and track Zydus Wellness Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Food Products rankingFinancials of Zydus Wellness Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Zydus Wellness Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 713 | 702 | 440 | 403 | 783 | 841 | 493 | 462 | 913 | 861 | 650 | 965 | 1,485 |
| Expenses + | 568 | 586 | 423 | 390 | 620 | 686 | 473 | 447 | 723 | 705 | 628 | 904 | 1,215 |
| Operating Profit | 145 | 116 | 17 | 13 | 162 | 155 | 20 | 15 | 190 | 156 | 23 | 61 | 270 |
| OPM % | 20% | 17% | 4% | 3% | 21% | 18% | 4% | 3% | 21% | 18% | 4% | 6% | 18% |
| Other Income + | -6 | -12 | 4 | 3 | 4 | 5 | 10 | 4 | 1 | 3 | -33 | -6 | 1 |
| Interest | 5 | 5 | 6 | 6 | 6 | 4 | 1 | 3 | 4 | 2 | 16 | 41 | 39 |
| Depreciation | 7 | 6 | 6 | 6 | 6 | 5 | 5 | 5 | 13 | 11 | 25 | 56 | 55 |
| Profit before tax | 126 | 93 | 9 | 4 | 154 | 152 | 24 | 10 | 173 | 145 | -51 | -42 | 177 |
| Tax % | -15% | -18% | 31% | 92% | 3% | 3% | 12% | 37% | 1% | 12% | 4% | -4% | 9% |
| Net Profit + | 145 | 110 | 6 | 0 | 150 | 148 | 21 | 6 | 172 | 128 | -53 | -40 | 162 |
| EPS in Rs | 4.57 | 3.47 | 0.19 | 0.01 | 4.72 | 4.64 | 0.66 | 0.20 | 5.40 | 4.02 | -1.66 | -1.25 | 5.09 |
Financials of Zydus Wellness Ltd
Profit & Loss
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 431 | 397 | 431 | 513 | 843 | 1,767 | 1,867 | 2,009 | 2,255 | 2,328 | 2,709 | 3,961 |
| Expenses + | 331 | 305 | 331 | 387 | 658 | 1,446 | 1,522 | 1,664 | 1,918 | 2,020 | 2,329 | 3,451 |
| Operating Profit | 100 | 91 | 99 | 125 | 185 | 321 | 344 | 345 | 337 | 308 | 380 | 510 |
| OPM % | 23% | 23% | 23% | 24% | 22% | 18% | 18% | 17% | 15% | 13% | 14% | 13% |
| Other Income + | 28 | 32 | 32 | 35 | 28 | -33 | -123 | 10 | -5 | -0 | 19 | -34 |
| Interest | 0 | 0 | 1 | 2 | 30 | 140 | 84 | 26 | 16 | 24 | 12 | 98 |
| Depreciation | 8 | 7 | 7 | 9 | 13 | 26 | 25 | 24 | 25 | 24 | 28 | 147 |
| Profit before tax | 120 | 117 | 124 | 150 | 171 | 121 | 112 | 306 | 291 | 260 | 359 | 230 |
| Tax % | 7% | 10% | 10% | 9% | -0% | -17% | -6% | -1% | -7% | -3% | 3% | 14% |
| Net Profit + | 111 | 105 | 111 | 137 | 171 | 142 | 119 | 309 | 310 | 267 | 347 | 197 |
| EPS in Rs | 5.58 | 5.28 | 5.58 | 6.85 | 5.87 | 4.92 | 3.73 | 9.71 | 9.75 | 8.39 | 10.90 | 6.20 |
| Dividend Payout % | 22% | 25% | 23% | 23% | 17% | 20% | 27% | 10% | 10% | 12% | 11% | 19% |
Financials of Zydus Wellness Ltd
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 39 | 39 | 39 | 39 | 58 | 58 | 64 | 64 | 64 | 64 | 64 | 64 |
| Reserves | 367 | 439 | 518 | 652 | 3,329 | 3,403 | 4,504 | 4,780 | 5,059 | 5,294 | 5,608 | 5,762 |
| Borrowings + | 0 | 0 | 25 | 25 | 1,569 | 1,519 | 550 | 387 | 297 | 329 | 188 | 3,203 |
| Other Liabilities + | 102 | 89 | 100 | 112 | 503 | 610 | 548 | 461 | 413 | 462 | 582 | 1,279 |
| Total Liabilities | 508 | 568 | 682 | 829 | 5,459 | 5,590 | 5,666 | 5,692 | 5,833 | 6,148 | 6,442 | 10,308 |
| Fixed Assets + | 84 | 82 | 103 | 104 | 4,567 | 4,674 | 4,667 | 4,710 | 4,732 | 4,708 | 5,125 | 8,596 |
| CWIP | 0 | 0 | 0 | 0 | 10 | 4 | 4 | 12 | 13 | 10 | 15 | 23 |
| Investments | 0 | 94 | 30 | 148 | 46 | 110 | 0 | 27 | 70 | 78 | 36 | 5 |
| Other Assets + | 423 | 391 | 550 | 577 | 835 | 802 | 995 | 943 | 1,018 | 1,354 | 1,266 | 1,684 |
| Total Assets | 508 | 568 | 682 | 829 | 5,459 | 5,590 | 5,666 | 5,692 | 5,833 | 6,148 | 6,442 | 10,308 |
Financials of Zydus Wellness Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 69 | 90 | 77 | 69 | 149 | 259 | 287 | 237 | 92 | 246 | 380 | 226 |
| Cash from Investing Activity + | 29 | -28 | -72 | -59 | -4,092 | -17 | -10 | -59 | -85 | -178 | -207 | -2,910 |
| Cash from Financing Activity + | -27 | -58 | -6 | -2 | 4,052 | -260 | -216 | -234 | -138 | -26 | -186 | 2,698 |
| Net Cash Flow | 71 | 4 | -1 | 8 | 109 | -18 | 60 | -56 | -132 | 43 | -13 | 15 |
| Free Cash Flow | 72 | 86 | 46 | 61 | 132 | 235 | 269 | 162 | 47 | 220 | 315 | 126 |
| CFO/OP | 80% | 114% | 86% | 64% | 115% | 81% | 83% | 70% | 28% | 81% | 99% | 50% |
Financials of Zydus Wellness Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 1 | 3 | 3 | 6 | 42 | 24 | 18 | 26 | 34 | 44 | 49 | 35 |
| Inventory Days | 76 | 73 | 127 | 113 | 393 | 168 | 158 | 135 | 146 | 150 | 148 | 178 |
| Days Payable | 146 | 191 | 264 | 254 | 662 | 289 | 189 | 136 | 100 | 116 | 122 | 107 |
| Cash Conversion Cycle | -69 | -116 | -134 | -135 | -227 | -97 | -13 | 25 | 80 | 78 | 75 | 106 |
| Working Capital Days | -37 | -38 | -57 | -26 | -26 | -7 | -35 | -27 | 17 | 20 | 34 | 49 |
| ROCE % | 32% | 26% | 23% | 22% | 7% | 6% | 6% | 6% | 6% | 5% | 6% | 5% |
Guidance history
How Zydus Wellness Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY27 call → | 10–20% | Flat | Planned | — | — |
| Q4 FY26 call → | 10–20% | Flat | Planned | None planned | — |
| Q3 FY26 call → | 10–20% | Flat | Planned | — | — |
| Q2 FY26 call → | 10–20% | Flat | Planned | — | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
22 out of 100 — Cooling
Over the past year its share price has done worse than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | −5.1% | 56% |
| Last 6 months | −9.0% | 41% |
| Last 3 months | −19.9% | 22% |
The price is 23.2% below its all-time high of ₹602.5 (20 Jul 2026). Stocks more than 20% below their peak have their score halved, so 43 became 22.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Zydus Wellness Ltd: 0.4 × 56 + 0.4 × 41 + 0.2 × 22 = 43, halved to 22 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 30 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Zydus Wellness Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Food Products this season
- Prataap Snacks Ltd (Q2 FY27)
Q2 FY27 income from operations was ₹540.95 crore, a 25.9% increase year-on-year (YoY). Key results statement takeaways from Prataap Snacks Ltd's Q2 FY27 results
- Madhusudan Masa (Q2 FY27)
4,158.28 lakh (Q2 2025), approximately +118% YoY. Key results statement takeaways from Madhusudan Masala Ltd's Q2 FY27 results statement — and how it ranks agai
- Vadilal Industries Ltd (Q2 FY27)
Revenue from operations for the quarter ended September 30, 2026: ₹462.56 crore (Consolidated, Page 11) . Key results statement takeaways from Vadilal Industrie
- Wardwizard Foods & Beverages Ltd (Q1 FY27)
Revenue for Q1 FY27 (June 2026 quarter) is ₹17.03 Cr, up from ₹13.20 Cr in Q1 FY26, reflecting a strong year-on-year growth. Key investor presentation takeaways